SPX3,825.33+39.95 1.06%
DIA310.85+3.03 0.98%
IXIC11,127.85+99.11 0.90%

Cogent Biosciences' Phase 2 Trial Data Shows Clinical Activity of Bezuclastinib for Treatment of Hematologic Disorder

MT Newswires · 06/10/2022 03:35

Please log in to view news